This action might not be possible to undo. Are you sure you want to continue?
Cross section analysis of
BEXIMCO PHARMACUTICALS Ltd. &
LIBRA PHARMACUTICALS Ltd.
Background of the study
Beximco Pharmaceuticals Ltd.(BPL) has been the trendsetter in Bangladesh Pharmaceutical Market since its inception in 1979. Over the last decade BPL actually rose to a new standard – moving beyond manufacturing quality medicines to win mind share of patients, physicians, shareholders, business partners, and communities where we work and live. Our dedication to add more value to the common wealth of the society compounded by innovative strategies for growth and diversification, pioneering role in bringing new technology and implementing new ideas, and commitment for total quality management distills the glory of our success. Today BPL is not merely a market leader. Most of the products that it actively markets enjoy leadership position demonstrating incomparable trust of the healthcare professionals. This is the reward for the outstanding quality of our products- at BPL we never compromise with the quality of our products so that our fellow citizens can live long, happy and better. BPL is the pioneer in introducing
medical service activities: publishing a full-fledged medical newsletter regularly, conducting clinical seminars and symposiums to have better understanding of various diseases and their management. BPL is the first national company who dared to diversify its business into manufacturing bulk drugs to integrate it self backwards as well as develop the nation’s pharma industry. While it would have been relatively easy to diversify the business into consumer products, BPL chose the harder path with a longterm vision. Today BPL is ready to face the challenge of scarce sourcing of Active
Pharmaceutical Ingredients (API) in the post-WTO era, with its advanced API manufacturing capability.
We try to focus on the report about the HR practice in BEXIMCOPHARMA. Bangladesh. Bangladesh 3 . Viewing the business as a mean of the social well-being of the investor. employees and the society and customers is the main vision of BPL. Bangladesh. Objective s: Our min objective is to prepare this report to know about the human recourse practice in an organization. The objectives of the study are as follows: ♦ To know the HRM policies followed in BPL. ♦ To identify the various avenues for improving the HRM policies of BPL. BPL’s passionate effort to achieve excellence in all spheres of its operations and its keen endeavor to incorporate innovative new technologies into its manufacturing practice puts it ahead of its contemporaries. The origin of our report is from our class. Beximco Pharmaceuticals Limited is committed to contribute to keep the earth clean. The company makes their best effort to ascertain the financial wealth and moral gains as a part of the process of the human civilization.He gave this report to learn the way and report writing.Origin of the report: The report originated from our course instructor . ♦ Suggesting strategies to improve the HRM policies of BPL.
survey and make observation. As it is a report about an organization so we have opportunity to collect data by reading documents from their web sites. The abundance of computer in our lab is very poor more than students demand. 3. In lab all computers are not connected with internet.Scope : Our assignment is only document basis so we have not opportunity to take interview. read newspaper. and utilize our personal observation. Those are noted below1. We don’t get much time to prepare this repot. As it is a report so our data is secondary data. Methodology: To complete our report and reach in a decision we use some method. 4 . 4. 2. Limitations: There we face some limitation to prepare this report. This is the time of early final examination. To collect information we search internet. so we can’t give more time to Prepare this report.
Chapter-2 Background of the Beximco Pharma 5 .
With decades of contract manufacturing experience with global MNCs. antireretrovirals.Background of the Beximco Pharma Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is consistently building upon its portfolio and currently producing more than 400 products in different dosage forms covering broader therapeutic categories which include antibiotics. Gulf nations. and each of them is guided by the same moral and social responsibilities the company values most. 6 . The company is the largest exporter of pharmaceuticals in the country and its state-of-theart manufacturing facilities are certified by global regulatory bodies of Australia. among others. Brazil. anti asthma inhalers etc. among many others. Ensuring access to quality medicines is the powerful aspiration that motivates more than 3000 employees of the organization. the company has been building a visible and growing presence across the continents offering high quality generics at the most affordable cost. antihypertensives. skilled manpower and proven formulation capabilities. antidiabetics.
About Beximco Pharma The company was incorporated in 1976 and commenced operations in 1980 with the manufacturing and marketing of products of Bayer AG. and the first to produce CFC free inhalers. Today Beximco Pharma is the largest exporter of pharmaceuticals in the country and the only company to win National Export Trophy (Gold).. BPL is also the first company to produce antiretroviral drugs (ARVs) locally. the company that produces intravenous fluids. its shares are actively traded in Dhaka Stock Exchange and Chittagong Stock Exchange. USA under licensing arrangements. In 1983. The company is the largest producer of Metered Dose Inhalers (MDIs) in the country. In 2005 Beximco Infusions Ltd. In the same year it completed the state-of-the-art oral solid dosage plant in compliance with the US FDA and UK MHRA standards. the company started manufacturing its own formulations and it launched export operation in 1992. was amalgamated with the parent company. 7 . Germany and Upjohn Inc. the highest national accolade for export. which has been approved by major global regulatory bodies. for record three times. As a public limited company. and Beximco Pharma has the unique distinction of being the only company in the country listed on AIM of London Stock Exchange.
Viewing the business as a mean of the social well-being of the investor. melt-in mouth tablets. 8 . In proprietary research. we are also developing a number of APIs to ensure availability of raw materials across the range of therapeutic classes.Research & Development With strong reverse engineering capability. chewable vitamins etc. sustained release formulations. The company makes their best effort to ascertain the financial wealth and moral gains as a part of the process of the human civilization. we focus principally on developing high quality generic formulations. Our growing innovation is evident from successful launching of a number of advanced formulations like multi-layer tablets. Our capabilities to produce hi-tech. With Our R&D team has successfully developed a range of CFC-free HFA MDIs. dispersible tablets. In addition. specialized niche products as well as drug delivery systems have been our core strength to transform BPL into an innovation-driven generic drug company. employees and the society and customers is the main vision of BPL. we conducted collaborative research with Ciba Specialty Chemicals of Switzerland. We also focus on simplifying manufacturing processes and improving cost efficiency. matching the profile of innovator products. Vision BPL’s passionate effort to achieve excellence in all spheres of its operations and its keen endeavor to incorporate innovative new technologies into its manufacturing practice puts it ahead of its contemporaries. Beximco Pharmaceuticals Limited is committed to contribute to keep the earth clean.
Ensuring full effort to enhance shareholders highest returns and growth of their asset also holds a key goal of the company. our customers. namely: our employees. We firmly believe that. Goals BPL has a strong market focus and is anticipating continued future growth by leveraging business capabilities and developing superior product brands and markets.Mission Each of our activities must benefit and add value to the common wealth of our society. The company is now moving to the world market and trying to expand their business worldwide with a good quality image. 9 . in the final analysis we are accountable to each of the constituents with whom we interact. Innovation of new products and satisfying the ever-changing need of consumers remains a top priority goal. our business associates. our fellow citizens and our shareholders.
and Agha Khan Hospital in Pakistan. for record three times. BPL has a global footprint in more than 45 countries across four continents and currently in the process of entering the emerging markets of CIS with increasing focus on regulated markets like EU and USA. the highest national accolade for export. MEDS and Kenyatta National Hospital (KNH) in Kenya. Beximco Pharma’s products are being supplied to renowned hospitals and institutions like Raffles Hospital and K K Women & Children Hospital in Singapore.Overseas Markets The company is the largest exporter of pharmaceuticals from Bangladesh and the only company to receive National Export Trophy (Gold). Besides the retail outlets. Kenya Myanmar Nepal Pakistan 10 . Jinnah Hospital.
Anti-glaucoma and eye vitamins and minerals etc. Cardiovascular Beximco Pharma has always been the leader in Bangladesh cardiovascular market with innovative product offerings to treat almost all type of cardiovascular diseases like Hypertension. Capsule. Beximco Pharma is the only company is Bangladesh to manufacture antiviral products to treat most serious infections of HIV (AIDS). Analgesics & Antipyretic Beximco Pharma is the largest provider of analgesic medicines in Bangladesh. Napa is the number one brand in terms of unit sales in Bangladesh and is available in 13 forms and strengths. developed by the R & D team at Beximco Pharma and provides 24-hour relief of allergic rhinitis with congestion (marketed under the brand name . Heart Failure. Products in this category also include a proprietary drug. The anti-infective products of Beximco Pharma are offered in different dosage forms: Tablet. a preparation of paracetamol. Now Beximco Pharma got around 20 Ophthalmic products in its product range covering various Therapeutic groups like Anti-infective. Hyperlipidemia. Anti-allergic. Coronary Artery Diseases. Artificial Tear. Arrhythmia etc. Paracetamol is the safest analgesic in the world for more than 50 years. led by the strong performance of Napa® .Pretin® D) Beximco Pharma will continue to build on its tradition of launching the generic versions of all the research molecules in this category. Beximco Pharma's amlodipine brand Amdocal® is the number 1 cardiovascular brand since 1996. 11 .Product Range Allergic Disorders Beximco Pharma has a strong focus to offer treatment solutions for both seasonal and perennial allergic rhinitis. Large volume and Small volume parenterals for systemic administration and Cream and Ointment for topical administration. Anti-inflammatory. Continuous enrichment of ophthalmic product range is going on. The journey of Beximco Pharma in this arena began with the licensing arrangement with Bayer AG of Germany for the manufacture and marketing of Incidal® in Bangladesh . Anti-infectives Beximco Pharma is one of the leading companies in the field of antibacterial and antiviral treatments offering a wide range of products. Eye Care Beximco Pharmaceuticals Ltd has introduced its vision unit in the year 2009.
is the number one brand in Bangladesh Pharmaceutical Market. insomnia. Endocrine & Diabetes Beximco Pharma offers wide range of products ensuring effective treatment of type II diabetes. epilepsy. Gliclazide. Oncology Beximco Pharma manufactures a generic version of Tamoxifen (Tamona®) which is being used successfully world wide for the treatment of breast cancer disease. Metformin. The company also has a proven drug for the treatment of nausea and vomiting associated with cancer therapy. pain of musculoskeletal origin are some of the diseases that limit the activities of daily life of millions of patients. Rheumatoid arthritis. dementia etc. chesty productive cough and other cough associated with common cold. Beximco Pharma's Neoceptin®-R. which is a H2 blocker used in the treatment of ulcer. Muscle spasm. Glimepiride. Beximco Pharma with its wide range of products in the musculoskeletal category offers effective treatment solution forr those patients. electrolytes and energy. depression. Pioglitazone Repaglinide etc. Muscloskeletal Osteoarthritis. Beximco Pharma will continue to build on its strengths in gastrointestinal category. schizophrenia. and other hyperacidity disorders. GERD. Intravenous Fluids Beximco Pharma has a strong product pipeline in the large volume intravenous fluids (IV) category for the treatment of critically ill patients who are hospitalized or in any emergency management for the replenishment of body fluids. It has the generic versions of all the leading research molecules including Glipizide.Central Nervous System Beximco Pharma has a wide range of CNS medication provide effective treatment of different diseases involving CNS including anxiety. Cough & Cold Wide product range of Beximco Pharma offers the doctors freedom to choose the right medication for different types of cough: dry cough. 12 . migraine. Beximco Pharma is also the largest manufacturer of IV fluids in Bangladesh. Gastrointestinal Beximco Pharma has a robust product line to treat diseases in the areas of gastroenterology. The products are being manufactured in its state-of-the-art plant using latest blow form and seal technology which ensures completely sterile and safe products for the patients.
'Preventer' and 'Controller' for the treatment of asthma and COPD. The company also undertakes contract manufacturing for GlaxoSmithKline for its 'reliever' brand. Skin Care Beximco Pharma's robust product line in the skin care category offers easy and convenient solution to wide range of skin diseases like fungal and bacterial infections. Beximco Pharma successfully developed and introduced country's fist CFC-free HFA based MDIs in September 2006. In collaboration with Europe's one of the leading manufacturers of specialty medical devices and respiratory drug development companies. It has a wide range of inhalers 'Reliever'. 13 . atopic dermatitis. eczema. Vitamins & Minerals Supplement Beximco Pharma's many brands in the vitamins and nutritional supplement category has gained trust of the physicians in treating various vitamins and nutritional deficiency symptoms.Other Products Beximco Pharma manufactures some other important products also. acne. and various other dry skin problems. other inflammatory skin diseases requiring corticosteroid therapy. Respiratory Beximco Pharma is the leading manufacturer of pressurized Metered Dose Inhalers (MDI) in Bangladesh and are among the few companies in the world manufacturing CFC (Chlorofluorocarbon) free MDIs. psoriasis.
Opportunities (External) Ability to Retain Growth & market Focus In difficult Operating Situations Ability to Exploit Opportunities of Patent Law as an LDC in International Market. Threats (External) Strong Competitors in Domestic & International Market.SWOT analysis The following SWOT analysis captures the key strengths and weaknesses within the company. Capability to Bring Innovation & product differentiation 3. Rising Trend of Material Price Strength (Internal) 1. World Class Professional Service Weakness (Internal) Insufficient Working Capital Not Operating in Low Cost Mark 14 . and describes the opportunities and threats facing BEXIMCO. Political Instability Government & International Regulations. Outstanding Product Quality 4. Employee Empowerment 2.
69 Graph: 3 2.5 2 1. Rules current ratio: Current ratio= Currentass et ` Currentlia bilites 6916737893 Beximco= 2321451642 14614587 Current ratio of =2. Rules of quick ratio: Quick ratio= Quickasset currentlia bilities Currentass et − inventory = currentlia bilities 15 . (1) Current ratio: A measure of liquidity calculates by dividing the firm’s current assets by its current liabilities.5 1 0.5 0 Libra Bexim co Interpretation: current ratio 2:1 is perfect Beximco should reduce there current asset that’s why will increase profitability but Libra should increase their current asset otherwise they may failure in business. (2) A measure of liquidity calculated by dividing the firm’s current assets minus inventory by its current liabilities.97 Current ratio of Libra= 205249503 =0.Performance Evaluation a) Liquidity ratio: A firm’s ability to satisfy its short-term obligations as they came due.
Quick ratio of Beximco= Quick ratio of Libra= Graph: 2. Rules of inventory turnover= Beximco inventory turnover= Libra inventory turnover = Graph: Costofgood sold Inventory 2566206626 1722953284 =1.5 1 0.5 0 Libra Bexim co 16 .5 2 1.5:1 is better Beximco should reduce there quick asset but Libra should increase their quick asset for met cup coming due.29 Libra Bexim co Interpretation: Quick ratio 1.48 times 233883005 81407309 =2.5 2 1. 1) Inventory turnover: Measure the activity or liquidity of a firm’s inventory.5 1 0. (b) Activity ratio: Measure the speed with which various account are converted into sales of cash-inflow or outflows.87 times 3 2.23 141614587 − 81407309 205049503 =0.5 0 6916737893 −1722953284 2321451642 =2.
Interpretation: The average age of inventory of Libra is (365/2. (2)Average collection period: The average amount of times needed of collect account receivable.78 days 60 50 40 30 20 10 0 Libra Bexim co Interpretation: The ACP meaningful only relation to firm credit terms.085 A/ p 38086911 =4.48=247 days. Rules of ACP= Averagesal esperday Beximco ACP= 694111730 =52.42days 640775 60 50 40 30 20 10 0 Libra Bexim co 17 .87) =127 days. (3)Average payment period:The App is the amount of time needed to pay accounts payable.7 A/ R Libra ACP = Graph: 29983238 1006923 =29. It is better than Beximco 365/1. Rrules of App: Averagepur chaseperda y Beximco app: Libra app: 409898122 =58. Libra ACP is lower than Beximco.04 days 13337684 .30days 7030703 . So Libra is better than Beximco.
the more efficiently its asset have been used. 18 .4 0. (4)Total asset turnover: Indicates the efficiency with the firm uses its assets to generate sales.6 0.Graph: Interpretation: The average payment period is meaningful only in relation to the ACT ented to the firm.8 0.87times.24times 1989193342 2 367526844 =0. C(1) : Debt ratio: Measures the proportion of total assets financed by the firms creditors.2 0 Libra Bexim co Interpretation:The higher a firm total asset turnover. 424725342 Graph: 1 0.SoLIBRA is better than BEXIMCO.So Beximco is better then Libra.Beximco: Libra: 4868254915 =0. Rules: Total asset turnover= sales Totalasset .
23 19 .The higher this ratio the grater the firms degree of indebtedness and the more financial leverage it has .45 27947137 Libra: 2 1 6 1 5 5 6 3 =1.7% 424725342 Graph: 80 60 40 20 0 Libra Beximco Interpretation:This value indicates that the company has financed close to half of its asset with debt.Rules: Totalliabi lities Totalasset 9006226810 =0. (2)Times interest earned ratio: Measure the firms ability to make contractual interest payment sometime called interest earned ratio. So libra is better than Beximco.452=45.2% 1989193342 2 Beximco: Libra: 338474038 =0. Rules: EBIT Interest Beximco: 1001282411 289427992 =3.797=79.
So.23 times. Rules = Grossprofi t sales 2302048289 4868254915 Beximco: Libra: =0. 20 .3.5 3 2.4% 367562844 Graph: 50 40 30 20 10 Libra Beximco . 0 Interpretation: The higher the gross profit margin is better.364=36. So Beximco is better then Libra.5 2 1.5 0 Libra Beximco Interpretation: Beximco 3. (D).472=47.Beximco is better than Libra.Profitability ratio: 1) Gross profit margin: Measures the percentage of each sales dollar remaining after the firm has paid for its goods.45 time able to able to pay interest and able to pay interst 1.5 1 0.2% 133643389 =0.
5% 27947137 367562844 = 7.205=20.128=12. Rules: Operating Profit sales Beximco= Libra= 1001282411 4868254915 = 0.12=1. Beximco is better then Libra (2). So.8% 4371801 =0.2% 367526844 Graph: 14 12 10 8 6 4 2 0 Libra Beximco Interpretation: The higher the firm net profit margin is better. taxes and preferred stock dividends are deducted.6% Graph: 21 . the “pure profits” earned on each sales dollar.(3)Net profit margin: Measure the percentage of each dollar remaining after all cost and expenses Rule: EACS Sales 264740307 4868254915 Beximco: Libra: =0.Operating profit margin: Measures the percentage of each sales dollar remaining after all costs and expenses other than interest.
Rules: EACS Totalasset 264740307 = 0. So Beximco is better than Libra.031=3. Beximco is better than Libra. 4.5 1 0.5 0 Libra Bexim co Interpretation: The higher the firms return on total asset is better.25 20 15 10 5 Libra Bexim co Interpretation: The operation profit margin measure the percentage of each sales dollar remaining after all costs & expenses .5 3 2.5 2 1. 22 . Return on total assets : Measures the overall effectiveness of management in generating profits with its available assets.0% 3. so. also called the return on investment.1% 1989193342 2 0 Beximco= Libra= Graph: 4371801 424725342 = 0.1=1. (5)Return on common equity: Measures the return earned on the common stockholder’s investment in the firm.
E) Market Ratio: Relate a firm’s market value. as measured by its current share price.8 5. So Beximco is better than Libra.8 Beximco: Libra: 1 0 =2. Rules: Marketpric epershare EPS 4.42times 4.4 5.1% 5. to certain accounting values.2 5 Libra Bexim co Interpretation: The higher return on common equity better from any firms.Rules: commonstoc kequity Beximco= Libra= Graph: 624740307 = 0. the higher the P/E ratio.7% 1088570661 4 EACS 4371801 86251304 = 5.93 Graph: 23 . the greater the investor confidence.6 5.1 3 100 =2.86times 34 . 1) P/E Ratio: Measures the amount that investors are willing to pay for each dollar of a firm’s earning.057=5.
6 2.ofshareout s tan ding EPS of Beximco= EPS of Libra= Graph: 624740307 151149296 EAT (earningaft ertext ) = 4.9 2. So Libra is better than Beximco.8 2. So. Findings 24 . # Earning per share(EPS): Rules of EPS: No .93 125160 35 30 25 20 15 10 5 0 Libra Bexim co Interpretation: EPS reprocess the number of dollar earned during the period on behalf of each outstanding share of common stock.3 2.2 Libra Bexim co Interpretation: The higher the P/E Ratio the grater the investor confidence.5 2.7 2.4 2.13 4371801 =34.2. here Libra Pharma’s EPS is better than Beximco Pharma.
A considerable volume of applications is dropped in the organizations as a result of the exposure created in the job fairs. The organization should regularly follow this procedure to build a productive and valuable workforce. 25 . 5. The organization could control the size of applicants’ pool by using more clear and specific statements in the ad in terms of the minimum educational degree. Bangladesh could participate in the job fairs for their recruitment. preferred institutions and other necessary criteria based on which the initial screening of the applications were conducted. The HR Department should look into the matter of consuming more time in the process of calling the applicants after their responses very seriously. 2. competitive corporate world. The company should be prepared the standard human resource planning. The assessment center approach is designed to identify the essential expertise of the candidates that enable to locate and select the right person for a managerial. The organization can promote its image as a potential recruiter through its successful participation in the job fairs. the organization should welcome new ideas as well as fresh –starters to trigger innovative ways to nature overall workforce competence. 3. 4. The in –house circulars within the group also act as a useful device to find the right person of the right job. The manager – training program of the company is a good way to groom a to -be – manager for the probable vacancy in the future. But this should also be followed in selecting the entry-level managers too. To cope with the ever-changing. The selection tools and procedures used in this program have also provided to be very effective. The OMR process practiced in the organization is a very effective tool to fill probable vacancy. This method is formally followed only in the manager trainee selection system.1. BCCP. Because the success and failure of the organization is highly depend on the proper human resource planning.
Side by side the HRD manager should evaluate the different positions of employees in the organization in order to establish the well conceived for pay-structure. The company should follow both on-the-job and off-the –job method training when they are training their employees. The HRD manager should prepare the standard promotion policy for the employees of the organization. Here it is noticeable that the HRD manager should appraise the performance of all employees in the organization without showing any discrimination. political influence and whatsoever. Because job analysis serves the cornerstone of all human resource functions in an organization. The company can recruited also for campus recruiting that could bring a yield of highly educated fresh-starters for the entry-level the organization could arrange seminars in the top business schools country. the HRD manager should be established the standard. 26 .6. The HRD manager should established the standard pay structure for the employees of the organization in order to reduce the high turnover of employees. 11. Before appraising the performance of employees in the organization properly.Also the company should facilitate online CV-posting system that is a very popular and effective practice used by the top business organizations. 10. Here it is very much important that the employees should get the promotion based on the performance not the nepotism. The HRD manager of the company should be analyzed the organizational jobs properly. 8. 9. 7.
Developing plans in a dynamic situation demands critical analysis of the situation and strict adhering to the core principal of the organization. As Beximco Pharma is decentralized organization and core values are cherished by everyone within the organization. The Bangladesh government should also be considerable and cooperative to help the businesses flourish. The sector consistently creates job opportunities for highly qualified people. relentless contribution and dedication of the organizations human resource management is very much needed. To be successful. 27 . With the development of healthcare infrastructure and increase of health awareness and the purchasing capacity of people. while at the same time maintaining a healthy competitiveness in respect of the most essential drugs. Healthy growth is likely to encourage the pharmaceutical companies to introduce newer drugs and newer research products. So. it is a great responsibility for Beximco Pharma as well as other companies in this industry to concentrate on quality product and quality service to take this industry towards further success.Conclusion Pharmaceutical Industry has grown in Bangladesh in the last two decades at a considerable rate. To compete in international as well as in local market in adverse situation the HR managers work has become much more difficult in today’s ever changing business environment. As one of leading pharmaceutical manufacturer Beximco Pharma plays a vital role in the industry as well as in the national economy. Pharmaceutical companies are either directly or indirectly contributing largely towards raising the standard of healthcare through enabling local healthcare personnel to gain access to newer products and also to latest drug information. this pharmaceutical industry is expected to grow at a higher rate in future. operating in dynamic situation is easier than it seems.
beximcopharma.com www.Bibliography: www.google.bing.com 28 .com www.
This action might not be possible to undo. Are you sure you want to continue?
We've moved you to where you read on your other device.
Get the full title to continue listening from where you left off, or restart the preview.